{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"97.5","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"97.5","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"97.5","value":"0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"52.2","value":"0"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"97.5","value":"0"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"60.2","value":"0"},{"groupId":"OG006","lowerLimit":"3.2","upperLimit":"65.1","value":"25"},{"groupId":"OG007","lowerLimit":"0.1","upperLimit":"27.3","value":"6"},{"groupId":"OG008","lowerLimit":"0","upperLimit":"70.8","value":"0"},{"groupId":"OG009","lowerLimit":"0","upperLimit":"36.9","value":"0"},{"groupId":"OG010","lowerLimit":"0","upperLimit":"97.5","value":"0"},{"groupId":"OG011","lowerLimit":"0.4","upperLimit":"57.9","value":"14"},{"groupId":"OG012","lowerLimit":"3.7","upperLimit":"71.0","value":"29"},{"groupId":"OG013","lowerLimit":"1.6","upperLimit":"38.3","value":"13"},{"groupId":"OG014","lowerLimit":"0.4","upperLimit":"64.1","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants achieving stringent complete response (sCR), very good partial response (VGPR), partial response (PR) or minimal response (MR) for multiple myeloma (MM); CR or PR for Non-Hodgkin's Lymphoma (NHL); CR, CRp, CRi or PR for Acute Myeloid Leukemia (AML); CR, MR or PR for Myelodysplastic Syndrome (MDS) using the International Working Group (IWG) response criteria and IWG response criteria in myelodysplasia.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"NUMBER","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 86.9 weeks","title":"Part 1: Overall Response Rate (ORR)- Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}